Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Current Epidemiology of Surgical Sepsis: Discordance Between Inpatient Mortality and 1-year Outcomes.

Brakenridge SC, Efron PA, Cox MC, Stortz JA, Hawkins RB, Ghita G, Gardner A, Mohr AM, Anton SD, Moldawer LL, Moore FA.

Ann Surg. 2019 Sep;270(3):502-510. doi: 10.1097/SLA.0000000000003458.

PMID:
31356275
2.

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).

Annibali O, Hohaus S, Marchesi F, Cantonetti M, Di Rocco A, Tomarchio V, Di Napoli A, Pelliccia S, Battistini R, Anticoli Borza P, Abruzzese E, Cenfra N, Andriani A, Tesei C, Alma E, Palombi F, Pupo L, Petrucci L, Becilli M, Maiolo E, Bellesi S, Cuccaro A, D'Alò F, Cox MC.

Leuk Lymphoma. 2019 Jul 1:1-9. doi: 10.1080/10428194.2019.1633628. [Epub ahead of print]

PMID:
31259651
3.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.

Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F.

Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6.

PMID:
31171545
4.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
5.

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

Cox MC, Pelliccia S, Marcheselli L, Battistini R, Arcari A, Borza PA, Patti C, Casaroli I, di Landro F, Di Napoli A, Fabbri F, Caridi M, Tafuri A, Bocci G, Musuraca G.

Invest New Drugs. 2019 Jun;37(3):548-558. doi: 10.1007/s10637-019-00769-5. Epub 2019 Apr 26.

PMID:
31028663
6.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

PMID:
30940746
7.

Relapsing Long-Lasting Garcin Syndrome Revealing Skull Base Diffuse B Cell Lymphoma: The Diagnosis through the "Hartel's Route".

Casolla B, Candela S, Ciacciarelli A, Ciolli L, Romano A, Acqui M, Cox MC, Sette G, Orzi F.

J Neurol Surg B Skull Base. 2019 Feb;80(1):105-108. doi: 10.1055/s-0038-1657794. Epub 2018 Jun 8.

PMID:
30733909
8.

The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.

Marcheselli R, Franceschetto A, Sacchi S, Bari A, Levy I, Pizzichini P, Prosperi D, D'Apollo R, Massi L, Casolo A, Pozzi S, Marcheselli L, Tadmor T, Prandini N, Cox MC.

Leuk Lymphoma. 2019 Aug;60(8):1958-1964. doi: 10.1080/10428194.2018.1564049. Epub 2019 Jan 28.

PMID:
30689474
9.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.

Ann Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539.

10.

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.

Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER.

Am J Surg Pathol. 2019 Apr;43(4):435-445. doi: 10.1097/PAS.0000000000001203.

PMID:
30585824
11.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network.

Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. No abstract available.

PMID:
30407625
12.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, Tyrrell V, Khuong-Quang DA, Pinese M, Gayevskiy V, Cohn RJ, Lau LMS, Reynolds M, Cox MC, Gifford A, Rodriguez M, Cowley MJ, Ekert PG, Marshall GM, Haber M.

Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.

13.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS.

Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.

14.

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.

Cencini E, Sicuranza A, Fabbri A, Ferrigno I, Rigacci L, Cox MC, Raspadori D, Bocchia M.

Br J Haematol. 2019 Jan;184(2):223-231. doi: 10.1111/bjh.15582. Epub 2018 Sep 11.

PMID:
30203425
15.

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.

Halalsheh H, McCarville MB, Neel M, Reynolds M, Cox MC, Pappo AS.

Pediatr Blood Cancer. 2018 Oct;65(10):e27271. doi: 10.1002/pbc.27271. Epub 2018 Jun 12.

PMID:
29893456
16.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

17.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.

Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Erratum in: Lancet Oncol. 2018 May;19(5):e229.

18.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

19.

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Cox MC, Musuraca G, Battistini R, Casaroli I, Zoli V, Anticoli-Borza P, Arcari A, Naso V, di Landro F, Fabbri F, Tafuri A, Bocci G, Merli F.

Br J Haematol. 2018 Dec;183(5):819-822. doi: 10.1111/bjh.15039. Epub 2017 Nov 28. No abstract available.

PMID:
29193017
20.

Improving Provision of Care for Long-term Survivors of Lymphoma.

Ciavarella S, Minoia C, Quinto AM, Oliva S, Carbonara S, Cormio C, Cox MC, Bravo E, Santoro F, Napolitano M, Spina M, Loseto G, Guarini A.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e1-e9. doi: 10.1016/j.clml.2017.08.097. Epub 2017 Aug 17. Review.

PMID:
28916153
21.

The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma.

Cox MC, Di Napoli A, Fabbri A, Cencini E, Ruco L.

Br J Haematol. 2018 Sep;182(5):741-742. doi: 10.1111/bjh.14873. Epub 2017 Aug 17. No abstract available.

PMID:
28832947
22.

Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma.

Di Napoli A, Pepe G, Giarnieri E, Cippitelli C, Bonifacino A, Mattei M, Martelli M, Falasca C, Cox MC, Santino I, Giovagnoli MR.

PLoS One. 2017 Jul 17;12(7):e0181097. doi: 10.1371/journal.pone.0181097. eCollection 2017.

23.

Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.

Battella S, Cox MC, La Scaleia R, Di Napoli A, Di Landro F, Porzia A, Franchitti L, Mainiero F, Ruco L, Monarca B, Santoni A, Palmieri G.

Cancer Immunol Immunother. 2017 Oct;66(10):1295-1306. doi: 10.1007/s00262-017-2026-7. Epub 2017 May 29.

PMID:
28555258
24.

TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents.

Picchianti Diamanti A, Laganà B, Cox MC, Pilozzi E, Amodeo R, Bove M, Markovic M, Di Rosa R, Salemi S, Sorgi ML, Rosado MM, D'Amelio R.

J Transl Med. 2017 Feb 21;15(1):38. doi: 10.1186/s12967-017-1135-6.

25.

Patient-centered treatment in atrial fibrillation.

Cox MC, Gulati VK.

JAAPA. 2016 Dec;29(12):1-4.

PMID:
27898562
26.

Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.

Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Pozzi S, Ferrari A, Baldini L, Gobbi P, Aviv A, Pugliese G, Federico M, Polliack A, Sacchi S.

Hematol Oncol. 2017 Dec;35(4):561-566. doi: 10.1002/hon.2359. Epub 2016 Oct 28.

27.

Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.

Bari A, Marcheselli L, Marcheselli R, Pozzi S, Cox MC, Baldessari C, Ferri P, Gobbi P, Baldini L, Tadmor T, Musto P, Federico M, Sacchi S.

Br J Haematol. 2018 Feb;180(4):600-602. doi: 10.1111/bjh.14406. Epub 2016 Oct 26. No abstract available.

28.

NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.

Lapenta C, Donati S, Spadaro F, Castaldo P, Belardelli F, Cox MC, Santini SM.

J Immunol. 2016 Aug 1;197(3):795-806. doi: 10.4049/jimmunol.1600262. Epub 2016 Jun 29.

29.

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U.

Leuk Lymphoma. 2017 Jan;58(1):226-229. Epub 2016 Jun 2. No abstract available.

PMID:
27252040
30.

Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A.

Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. doi: 10.1002/pbc.26026. Epub 2016 Apr 19.

31.

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

Zinzani PL, Pellegrini C, Cerciello G, Monaco F, Volpetti S, Peli A, Angelucci E, Corradini P, Cox MC, Guarini A, Musso M, Bresciani P, Amato G, Billio A, Caparrotti G, Figuera A, Nassi L, Gaudio F, Grossi A, Onida F, Merli M, Rigacci L, Argnani L.

Leuk Lymphoma. 2016 Oct;57(10):2370-4. doi: 10.3109/10428194.2015.1137292. Epub 2016 Feb 17.

PMID:
26732313
32.

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D.

Leuk Lymphoma. 2016 Aug;57(8):1823-30. doi: 10.3109/10428194.2015.1106536. Epub 2015 Dec 15.

PMID:
26666433
33.

Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis.

Cox MC, Kusters JM, Gidding CE, Schieving JH, van Lindert EJ, Kaanders JH, Janssens GO.

Radiat Oncol. 2015 Nov 24;10:241. doi: 10.1186/s13014-015-0547-9.

34.

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.

Cencini E, Fabbri A, Rigacci L, Lazzi S, Gini G, Cox MC, Mancuso S, Abruzzese E, Kovalchuk S, Goteri G, Di Napoli A, Bono R, Fratoni S, Di Lollo S, Bosi A, Leoncini L, Bocchia M.

Hematol Oncol. 2017 Mar;35(1):69-78. doi: 10.1002/hon.2249. Epub 2015 Aug 7.

PMID:
26251194
35.

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Proposal for a Monitoring Protocol.

Santanelli di Pompeo F, Laporta R, Sorotos M, Di Napoli A, Giovagnoli MR, Cox MC, Campanale A, Longo B.

Plast Reconstr Surg. 2015 Aug;136(2):144e-151e. doi: 10.1097/PRS.0000000000001416.

PMID:
26218387
36.

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.

Battella S, Cox MC, Santoni A, Palmieri G.

J Leukoc Biol. 2016 Jan;99(1):87-96. doi: 10.1189/jlb.5VMR0415-141R. Epub 2015 Jul 1. Review.

PMID:
26136506
37.

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Tadmor T, Bari A, Marcheselli L, Sacchi S, Aviv A, Baldini L, Gobbi PG, Pozzi S, Ferri P, Cox MC, Cascavilla N, Iannitto E, Federico M, Polliack A.

Mayo Clin Proc. 2015 Jun;90(6):756-64. doi: 10.1016/j.mayocp.2015.03.025.

38.

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.

Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, Zingoni A, Mainiero F, Ruco L, Monarca B, Santoni A, Palmieri G.

Oncoimmunology. 2015 Jan 7;4(3):e990773. eCollection 2015 Mar.

39.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U.

Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19.

PMID:
25241999
40.

The immunoglobulin isotype matters in diffuse-large-B-cell lymphoma with serum paraproteinaemia.

Cox MC, Di Napoli A, Scarpino S, Ruco L.

Ann Hematol. 2015 Apr;94(4):681-2. doi: 10.1007/s00277-014-2201-2. Epub 2014 Sep 6. No abstract available.

PMID:
25193355
41.

Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.

Cox MC, Di Napoli A, Scarpino S, Salerno G, Tatarelli C, Talerico C, Lombardi M, Monarca B, Amadori S, Ruco L.

PLoS One. 2014 Apr 4;9(4):e93903. doi: 10.1371/journal.pone.0093903. eCollection 2014.

42.

Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey.

Marignani M, Marzano A, Begini P, Vitolo U, Luminari S, Levis A, Deli I, Gigante E, De Santis E, delle Fave G, Monarca B, Cox MC.

Leuk Lymphoma. 2014 Nov;55(11):2564-71. doi: 10.3109/10428194.2013.879712. Epub 2014 Mar 7.

PMID:
24471911
43.

Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.

Bossi D, Carlomagno F, Pallavicini I, Pruneri G, Trubia M, Raviele PR, Marinelli A, Anaganti S, Cox MC, Viale G, Santoro M, Di Fiore PP, Minucci S.

Mol Oncol. 2014 Mar;8(2):221-31. doi: 10.1016/j.molonc.2013.11.004. Epub 2013 Nov 19.

44.

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era.

Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, Baldini L, Brugiatelli M, Federico M, Polliack A.

Haematologica. 2014 Jan;99(1):125-30. doi: 10.3324/haematol.2013.088161. Epub 2013 Aug 9.

45.

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.

Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM.

J Clin Oncol. 2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922. Epub 2013 Jul 15. No abstract available.

46.

Cutaneous manifestations of systemic non-Hodgkin lymphomas (NHL): study and review of literature.

Carlesimo M, Narcisi A, Rossi A, Saredi I, Orsini D, Pelliccia S, Aloe Spiriti MA, Mari E, Cox MC.

J Eur Acad Dermatol Venereol. 2014 Feb;28(2):133-41. doi: 10.1111/jdv.12201. Epub 2013 Jun 24. Review.

PMID:
23796025
47.

Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.

Pelliccia S, Di Napoli A, Naso V, Alma E, Rebecchini C, Cox MC.

Eur J Haematol. 2013 Aug;91(2):183-6. doi: 10.1111/ejh.12141. Epub 2013 Jun 28.

PMID:
23692265
48.

Metronomic chemotherapy for cancer treatment: a decade of clinical studies.

Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P.

Cancer Chemother Pharmacol. 2013 Jul;72(1):13-33. doi: 10.1007/s00280-013-2125-x. Epub 2013 Mar 9. Review.

PMID:
23475105
49.

Commentary on "Mediation Analysis and Categorical Variables: The Final Frontier" by Dawn Iacobucci.

Mackinnon DP, Cox MC.

J Consum Psychol. 2012 Oct 1;22(4):600-602. Epub 2012 Apr 12. No abstract available.

50.

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, Pinto A.

Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20.

PMID:
23167437

Supplemental Content

Support Center